SCHEMBL4724796

SCHEMBL4724796

CCCCN(C)c1nccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.40
HTR7 P34969 1/20 0.40
SCN1A P35498 1/20 0.38
SCN2A Q99250 1/20 0.38
SCN3A Q9NY46 1/20 0.38
TLR8 Q9NR97 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FBP1 P09467 1/20 0.34
MAPT P10636 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
AR P10275 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
FFAR2 O15552 1/20 0.32
LATS1 O95835 1/20 0.32
LATS2 Q9NRM7 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4723832 0.89 HTR7 (0.42) PPARGHTR7SCN1ASCN2ASCN3A
SCHEMBL4722034 0.83 SCN1A (0.42) HTR7SCN1ASCN2ASCN3ATLR8
SCHEMBL4698788 0.81 PPARG (0.38) PPARGHTR7SCN1ASCN2ASCN3A
SCHEMBL173416 0.80
SCHEMBL4723376 0.80 SCN1A (0.40) HTR7SCN1ASCN2ASCN3ATLR8
SCHEMBL4723360 0.80 SCN1A (0.40) HTR7SCN1ASCN2ASCN3ATLR8
SCHEMBL2858049 0.79 HTR7 (0.41) PPARGHTR7SCN1ASCN2ASCN3A
SCHEMBL3022750 0.79 POLB (0.44) PPARGHTR7SCN1ASCN2ASCN3A
SCHEMBL13634421 0.78 PPARG (0.41) PPARGHTR7SCN1ASCN2ASCN3A
SCHEMBL4894844 0.78 SCN1A (0.41) HTR7SCN1ASCN2ASCN3ATLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 PPARG 1458/4885HTR7 136/4885SCN1A 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.